Skip to main content

Influenza

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
NCT00735475 | PHASE 4 | INTERVENTIONAL

The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.

Trial Information
13 Sites
1268 Participants
Recruiting
65 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

North Central Arkansas Medical Association
Mountain Home,Arkansas,United States,72635
Covance CRU, Inc
Boise,Idaho,United States,83704
The University of Iowa
Iowa City,Iowa,United States,52242
Kentucky Pediatric Adult Research
Bardstown,Kentucky,United States,40004
Saint Louis University Medical Center
Saint Louis,Missouri,United States,63104
University of Rochester School of Medicine and Dentistry
Rochester,New York,United States,14642
Duke University Medical Center
Durham,North Carolina,United States,27704
Cincinnati Children's Hospital Medical Center
Cincinnati,Ohio,United States,45229
Covance CRU, Inc.
Portland,Oregon,United States,97239
Primary Physicians Research, Inc.
Pittsburgh,Pennsylvania,United States,15241
Clinical Partners, LLC
Johnston,Rhode Island,United States,02919
Vanderbilt Medical Center
Nashville,Tennessee,United States,37232
Covance CRU Inc.
Austin,Texas,United States,78752

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov